June 1, 2024Annals of the Rheumatic Diseases
Ab1569-HPR Clinical and Economic Burden of Polymyalgia Rheumatica in Patients With an Inadequate Response to Glucocorticoids or Glucocorticoids Taper in a Real-World Setting
Authors
Discussion
Loading...
Member takes
Implication
Retrospective cohort study reveals increased adverse events and healthcare costs in polymyalgia rheumatica with inadequate steroid taper, highlighting the need for steroid-sparing therapies.
Key Points
- Adverse events and healthcare resource utilization remain elevated for years in polymyalgia rheumatica patients with inadequate glucocorticoids taper response.
- Among 6054 patients, adverse event rates and healthcare costs stayed elevated through 54 months in those unable to successfully taper their glucocorticoids.
- Retrospective cohort analysis of Medicare claims demonstrates prolonged clinical burden, underscoring the urgent necessity for steroid sparing therapy in PMR.
Cite This Study
Curtis et al. (2024) studied this question.